Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CTSE_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CTSE_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CTSE_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CTSE_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CTSE_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
GO:0048002 | Colorectum | SER | antigen processing and presentation of peptide antigen | 19/2897 | 62/18723 | 1.96e-03 | 1.97e-02 | 19 |
GO:0019882 | Colorectum | SER | antigen processing and presentation | 28/2897 | 106/18723 | 2.52e-03 | 2.34e-02 | 28 |
GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
GO:001988212 | Liver | HCC | antigen processing and presentation | 65/7958 | 106/18723 | 7.06e-05 | 6.37e-04 | 65 |
GO:000247811 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen | 27/7958 | 38/18723 | 3.47e-04 | 2.42e-03 | 27 |
GO:004800212 | Liver | HCC | antigen processing and presentation of peptide antigen | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
GO:001648511 | Liver | HCC | protein processing | 121/7958 | 225/18723 | 4.01e-04 | 2.71e-03 | 121 |
GO:001988611 | Liver | HCC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 22/7958 | 30/18723 | 6.14e-04 | 3.82e-03 | 22 |
GO:001988411 | Liver | HCC | antigen processing and presentation of exogenous antigen | 31/7958 | 47/18723 | 9.90e-04 | 5.71e-03 | 31 |
GO:000250411 | Liver | HCC | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 24/7958 | 36/18723 | 2.95e-03 | 1.38e-02 | 24 |
GO:000249511 | Liver | HCC | antigen processing and presentation of peptide antigen via MHC class II | 22/7958 | 34/18723 | 7.46e-03 | 2.96e-02 | 22 |
GO:00198867 | Lung | IAC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 10/2061 | 30/18723 | 9.63e-04 | 1.16e-02 | 10 |
GO:00025046 | Lung | IAC | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 11/2061 | 36/18723 | 1.23e-03 | 1.42e-02 | 11 |
GO:00024788 | Lung | IAC | antigen processing and presentation of exogenous peptide antigen | 11/2061 | 38/18723 | 2.00e-03 | 2.01e-02 | 11 |
GO:00024956 | Lung | IAC | antigen processing and presentation of peptide antigen via MHC class II | 10/2061 | 34/18723 | 2.79e-03 | 2.52e-02 | 10 |
GO:00198848 | Lung | IAC | antigen processing and presentation of exogenous antigen | 12/2061 | 47/18723 | 4.05e-03 | 3.31e-02 | 12 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTSE | SNV | Missense_Mutation | rs782358758 | c.628G>C | p.Val210Leu | p.V210L | P14091 | protein_coding | tolerated(0.15) | probably_damaging(0.968) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
CTSE | SNV | Missense_Mutation | novel | c.813C>A | p.Phe271Leu | p.F271L | P14091 | protein_coding | tolerated(0.54) | possibly_damaging(0.859) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSE | insertion | Frame_Shift_Ins | novel | c.360_361insATTAATATATGTTATATAATATATAATATATT | p.Gln121IlefsTer49 | p.Q121Ifs*49 | P14091 | protein_coding | | | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
CTSE | insertion | Nonsense_Mutation | novel | c.814_815insCAGCCCTACCCCTAAGCCTCTATTAACTCCTTCCCAAA | p.Cys272SerfsTer9 | p.C272Sfs*9 | P14091 | protein_coding | | | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
CTSE | SNV | Missense_Mutation | | c.646T>C | p.Ser216Pro | p.S216P | P14091 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSE | SNV | Missense_Mutation | novel | c.934N>C | p.Val312Leu | p.V312L | P14091 | protein_coding | tolerated(0.07) | benign(0.085) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSE | SNV | Missense_Mutation | | c.55G>A | p.Gly19Arg | p.G19R | P14091 | protein_coding | tolerated(0.48) | benign(0.031) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CTSE | SNV | Missense_Mutation | novel | c.451N>A | p.Asp151Asn | p.D151N | P14091 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CTSE | deletion | Frame_Shift_Del | novel | c.1021delN | p.Leu341TyrfsTer71 | p.L341Yfs*71 | P14091 | protein_coding | | | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSE | SNV | Missense_Mutation | novel | c.638N>T | p.Pro213Leu | p.P213L | P14091 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |